Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282209 | 1.00 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL4282204 | 1.00 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL4719490 | 0.93 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL13387564 | 0.93 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL30581344 | 0.90 | GAA (0.51) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL16526220 | 0.88 | GAA (0.66) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8260235 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8259162 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8257128 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL28019672 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560650-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133953-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| US-6245761-B1 | NERVOUS SYSTEM, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2001-06-12 | — | — | US | disclosed |
| EP-0789688-A4 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |